| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1024879 | F | Inhibition of Vaccinia virus DNA synthesis in by rapid plate assay | Vaccinia virus | 93 | ALA1140145 | organism-based format | Scientific Literature | |
| 2. | ALA1024886 | F | Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as reduction in plaque formation up to 200 uM after 20 hrs | Vaccinia virus | 19 | ALA1140145 | organism-based format | Scientific Literature | |
| 3. | ALA1024887 | F | Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as protection from virus-induced lysis of cell monolayer up to 200 uM after 20 hrs | Vaccinia virus | 19 | ALA1140145 | organism-based format | Scientific Literature | |
| 4. | ALA1024888 | A | Cytotoxicity against african green monkey BSC1 cells up to 200 uM after 20 to 120 hrs WST-1 based assay | Chlorocebus aethiops | 19 | ALA1140145 | cell-based format | Scientific Literature | |
| 5. | ALA1054500 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | ALA1157539 | organism-based format | GSK Malaria Screening | |
| 6. | ALA1054501 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | ALA1157539 | organism-based format | GSK Malaria Screening | |
| 7. | ALA1054502 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | Plasmodium falciparum | 13,467 | ALA1157539 | organism-based format | GSK Malaria Screening | |
| 8. | ALA1054503 | F | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | Plasmodium falciparum | 13,467 | ALA1157539 | organism-based format | GSK Malaria Screening | |
| 9. | ALA1054504 | F | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | Homo sapiens | 13,467 | ALA1157539 | cell-based format | GSK Malaria Screening | |
| 10. | ALA1054505 | F | GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested | 13,467 | ALA1157539 | assay format | GSK Malaria Screening | ||
| 11. | ALA1040691 | F | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 12. | ALA1040692 | F | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | ALA1156829 | organism-based format | Novartis Malaria Screening | |
| 13. | ALA1040693 | T | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | Homo sapiens | 5,614 | ALA1156829 | cell-based format | Novartis Malaria Screening | |
| 14. | ALA1040694 | F | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 5,614 | ALA1156829 | assay format | Novartis Malaria Screening | ||
| 15. | ALA1614183 | F | PUBCHEM_BIOASSAY: High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv. (Class of assay: confirmatory) | 2,044 | ALA1201862 | assay format | PubChem BioAssays | ||
| 16. | ALA1614249 | B | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | Equus caballus | 42,059 | ALA1201862 | single protein format | PubChem BioAssays | |
| 17. | ALA1614307 | F | PUBCHEM_BIOASSAY: Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of Trypanosoma cruzi Replication. (Class of assay: confirmatory) [Related pubchem assays: 1885, 1968 ] | 4,058 | ALA1201862 | cell-based format | PubChem BioAssays | ||
| 18. | ALA1614453 | F | PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS Screen to Identify Cytotoxic Compounds of NIH3T3 cells. (Class of assay: confirmatory) [Related pubchem assays: 1885, 1968 ] | 4,024 | ALA1201862 | cell-based format | PubChem BioAssays | ||
| 19. | ALA1614459 | F | PUBCHEM_BIOASSAY: qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells. (Class of assay: confirmatory) | Drosophila | 88,408 | ALA1201862 | assay format | PubChem BioAssays | |
| 20. | ALA1614524 | F | PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS to Identify Compounds Cytotoxic to DRD Non-Viral Oncogenic Fibroblast. (Class of assay: confirmatory) [Related pubchem assays: 1674 (Project Summary), 1554 (Primary HTS)] | Homo sapiens | 1,147 | ALA1201862 | cell-based format | PubChem BioAssays |
The page will load shortly, Thanks for your patience!